In a new SLAS Technology auto-commentary, two authors of an article recently published in
(Abnormal Scar Identification with Spherical Nucleic Acid Technology) share more insight into this new method. In particular, the authors address point-of-care diagnosis and image acquisition, which are the primary bottlenecks in efficient disease diagnosis.
‘NanoFlare nanotechnology enables biopsy-free diagnosis of skin disease and progression monitoring in response to therapy. This unique method is a minimally-invasive, self-applied alternative that can reduce scarring and infection risks.
’
Authors David Yeo, Ph.D., and Prof. Chenjie Xu, Ph.D., of the School of Chemical and Biomedical Engineering at Nanyang Technological University (Singapore) use NanoFlare to enable biopsy-free disease diagnosis and progression monitoring in response to therapy.
The method is a minimally-invasive, self-applied alternative that can reduce scarring and infection risks; improve accessibility to disease diagnosis; provide timely feedback of treatment efficacy; and reduce healthcare personnel time and attention, hence the overall healthcare burden.
This vision of simplifying disease diagnosis using topically-applied nanotechnology could change the way skin diseases such as abnormal scars are diagnosed and managed.
Source: Eurekalert
Careers
